Oppenheimer initiated coverage of Prime Medicine (PRME) with an Outperform rating and $11 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRME:
- Largest borrow rate increases among liquid names
- Prime Medicine Reports 2025 Results, Advances Gene Editing Pipeline
- Prime Medicine reports FY25 EPS ($1.35) vs ($1.65) last year
- PRME Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Prime Medicine Advances Wilson Disease Pipeline With New Prescreening Study